NIH awards $3.37M for Universal Influenza Vaccine Phase II Clinical Trial Support

Contract Overview

Contract Amount: $3,370,663 ($3.4M)

Contractor: Guidehouse Digital LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2023-09-30

End Date: 2027-03-29

Contract Duration: 1,276 days

Daily Burn Rate: $2.6K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE

Place of Performance

Location: GALVESTON, GALVESTON County, TEXAS, 77555

State: Texas Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $3.4 million to GUIDEHOUSE DIGITAL LLC for work described as: NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE Key points: 1. Contract supports critical research for a universal flu vaccine. 2. Competition was full and open, suggesting market availability. 3. Risk is moderate due to clinical trial uncertainties. 4. Sector is healthcare/biotech R&D, a high-priority area.

Value Assessment

Rating: good

The award amount of $3.37M for a 4.5-year period appears reasonable for specialized clinical trial support services. Benchmarking against similar NIH contracts for Phase II trial support would provide a more precise assessment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

Full and open competition was utilized, indicating that multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and allows the government to select the best value.

Taxpayer Impact: The use of competitive bidding aims to ensure taxpayer funds are used efficiently for essential research.

Public Impact

Advancement of a universal flu vaccine could significantly reduce public health burdens and healthcare costs. Supports ongoing efforts to combat influenza, a persistent global health threat. Investment in advanced medical research aligns with national health priorities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls within the Professional, Scientific, and Technical Services sector, specifically supporting biomedical research and development. Spending in this area is crucial for public health advancements and innovation.

Small Business Impact

The data indicates this contract was awarded to GUIDEHOUSE DIGITAL LLC, a firm. There is no specific information provided regarding small business participation or subcontracting goals for this particular award.

Oversight & Accountability

The contract is managed by the National Institute of Allergy and Infectious Diseases (NIAID) within NIH. Standard government oversight for contract performance and financial management would apply.

Related Government Programs

Risk Flags

Tags

all-other-professional-scientific-and-te, department-of-health-and-human-services, tx, delivery-order, 1m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $3.4 million to GUIDEHOUSE DIGITAL LLC. NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE

Who is the contractor on this award?

The obligated recipient is GUIDEHOUSE DIGITAL LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $3.4 million.

What is the period of performance?

Start: 2023-09-30. End: 2027-03-29.

What is the projected impact of this universal flu vaccine on future public health preparedness?

A successful universal flu vaccine could drastically reduce the incidence of seasonal flu, minimize hospitalizations and deaths, and lessen the economic burden associated with widespread outbreaks. It would also enhance national preparedness for novel influenza strains and potential pandemics, offering a more stable and reliable defense than current strain-specific vaccines.

What are the primary risks associated with the contractor's ability to deliver on this clinical trial support?

Key risks include potential delays in patient recruitment for the Phase II trial, unforeseen scientific challenges in vaccine development, and the contractor's capacity to manage complex logistical and regulatory requirements. Performance issues could impact the trial's timeline and the overall progress towards a viable vaccine.

How does this investment compare to historical spending on influenza vaccine research and development?

This $3.37M award represents a specific investment in Phase II clinical trial support for a universal vaccine. Historical spending on influenza R&D is substantial and multifaceted, encompassing basic research, vaccine platform development, and multiple clinical trial phases across various government agencies and private entities. This contract is a component of a larger, ongoing national and global effort.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesOther Professional, Scientific, and Technical ServicesAll Other Professional, Scientific, and Technical Services

Product/Service Code: SUPPORT SVCS (PROF, ADMIN, MGMT)PROFESSIONAL SERVICES

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: TORP# 252

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 1676 INTERNATIONAL DRIVE, MCLEAN, VA, 22102

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,405,064

Exercised Options: $3,370,663

Current Obligation: $3,370,663

Actual Outlays: $605,443

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 75N98020D00086

IDV Type: IDC

Timeline

Start Date: 2023-09-30

Current End Date: 2027-03-29

Potential End Date: 2028-03-29 00:00:00

Last Modified: 2026-03-27

More Contracts from Guidehouse Digital LLC

View all Guidehouse Digital LLC federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending